Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D 1 , D 2 and D 3 receptors

By Perachon S.   Schwartz J.-C.   Sokoloff P.  

European Journal of Pharmacology, Vol. 366, Iss. 2, 1999-02 ,pp. : 293-300

Elsevier

Access to resources Recommend Favorite

Dopamine D2 Receptor-Mediated Inhibition of Dopaminergic Neurons in Mice Lacking D2L Receptors

By Centonze D.   Usiello A.   Gubellini P.   Pisani A.   Borrelli E.   Bernardi G.   Calabresi P.  

Neuropsychopharmacology, Vol. 27, Iss. 5, 2002-11 ,pp. : 723-726

Elsevier

Access to resources Recommend Favorite

Stereospecific modulation of the electrical activity of ascending dopaminergic as compared to serotoninergic pathways by preferential agonists and antagonists at dopamine D 3 receptors

By Lejeune F.   Audinot V.   Newman-Tancredi A.   Gluck L.   Peglion J.-L.   Millan M.J.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 405-406

Elsevier

Access to resources Recommend Favorite

Antidepressant drugs given repeatedly change the binding of the dopamine D 2 receptor agonist, [ 3 H]N-0437, to dopamine D 2 receptors in the rat brain

By Maj J.   Dziedzicka-Wasylewska M.   Rogoz R.   Rogoz Z.   Skuza G.  

European Journal of Pharmacology, Vol. 304, Iss. 1, 1996-05 ,pp. : 49-54

Elsevier

Access to resources Recommend Favorite

Effects of selective activation of dopamine D 2 and D 3 receptors on prolactin secretion and the activity of tuberoinfundibular dopamine neurons

By Durham R.A.   Eaton M.J.   Moore K.E.   Lookingland K.J.  

European Journal of Pharmacology, Vol. 335, Iss. 1, 1997-09 ,pp. : 37-42

Elsevier

Access to resources Recommend Favorite